Report Highlights

Medical Sensors in the U.S.: Market Overview

The U.S. medical sensors market was valued at USD 11.6 billion in 2024 and is forecast to reach USD 19.4 billion by 2032. Demand spans implantable pressure sensors, continuous glucose monitors, pulse oximetry, and hospital telemetry. Private innovators dominate product design: Medtronic and Abbott lead implantable and glucose sensing, Masimo leads pulse oximetry, and Texas Instruments and Analog Devices supply core sensing chips. Manufacturing clusters in Minnesota, Massachusetts, and California reflect this private leadership.

Government has been the dominant force in demand formation rather than product design. Medicare and Medicaid reimbursement, administered by the Centers for Medicare and Medicaid Services (CMS), sets the volume trajectory for home and outpatient monitoring. The Department of Veterans Affairs' Office of Connected Care adds procurement scale, while the FDA's Center for Devices and Radiological Health (CDRH) controls market entry under the Federal Food, Drug, and Cosmetic Act.

Policy-Driven Growth in U.S. Medical Sensors

Three mechanisms drive demand. First, the 21st Century Cures Act of 2016 codified the FDA Breakthrough Devices Program, which accelerates review for novel sensors addressing unmet clinical needs. Second, CMS implemented remote physiologic monitoring codes CPT 99454 and 99457 in 2019, converting sensor-generated data into billable services and lifting home monitoring adoption among Medicare beneficiaries with chronic conditions.

Third, the CHIPS and Science Act of 2022 funded domestic semiconductor capacity and created an advanced manufacturing investment credit under Section 48D of the Internal Revenue Code, which the One Big Beautiful Bill Act of 2025 subsequently enlarged. Lower chip input costs for U.S. sensor assemblers widen margins, while reimbursed recurring volume guarantees utilisation. Together these mechanisms convert policy into predictable, domestically anchored demand growth.

Regulatory Barriers and Compliance Costs in U.S. Sensors

Premarket clearance is the first barrier. FDA's CDRH administers 510(k) review under the fifth Medical Device User Fee Amendments (MDUFA V), with a 90-FDA-day goal for most submissions, while the standard 510(k) user fee exceeded USD 26,000 in FY2025. Manufacturers must also meet 21 CFR Part 820, which the amended Quality Management System Regulation (QMSR) aligns with ISO 13485:2016 from February 2, 2026, adding documentation and audit cost.

Connectivity adds a second layer. Wireless sensors must comply with Federal Communications Commission rules, including the Wireless Medical Telemetry Service under 47 CFR Part 95, Subpart H, and equipment authorisation delays add months to launch timelines. A Section 232 investigation into imported medical devices and components, opened by the Department of Commerce in September 2025, adds tariff exposure for firms importing sensor modules from Asia.

Policy-Created Opportunities in the U.S. Sensor Market

The Department of Veterans Affairs' Office of Connected Care offers a procurement channel for home telehealth sensors across its medical centers and community-based outpatient clinics. Vendors holding Federal Supply Schedule contracts through the VA National Acquisition Center can access this demand without building separate federal distribution networks, shortening sales cycles for mid-sized sensor firms.

The Section 48D credit creates an opening for domestic sensor assembly near new semiconductor fabs in Arizona, Oregon, and Texas. FDA Breakthrough Devices designation also grants priority review to non-invasive glucose and hemodynamic sensors, giving early-stage companies a faster route to Medicare coverage decisions and hospital purchasing commitments.

Market at a Glance

Leading Market Participants

• Medtronic
• Abbott Laboratories
• Dexcom
• Masimo
• Becton Dickinson
• Honeywell International
• TE Connectivity
• Analog Devices
• Texas Instruments
• Philips Healthcare

Regulatory and Policy Environment for U.S. Medical Sensors

The primary legislation is Chapter V of the Federal Food, Drug, and Cosmetic Act, administered by the FDA's CDRH. Section 524B, added by the Consolidated Appropriations Act, 2023, requires cyber devices to include a software bill of materials, security update plans, and vulnerability monitoring. Compliance also requires Medical Device Reporting under 21 CFR Part 803 and Unique Device Identification under 21 CFR Part 830, alongside the QMSR effective February 2, 2026.

Upcoming changes include MDUFA VI negotiations between FDA and industry ahead of reauthorization by September 2027, and CMS rulemaking on remote monitoring payment in the CY2027 Physician Fee Schedule. Relative to peers, the U.S. 510(k) pathway is faster than the EU Medical Device Regulation (EU) 2017/745, which requires notified body certification, and Canada's licence-based Medical Devices Regulations SOR/98-282 imposes comparable documentation burdens.

Long-Term Policy Outlook for U.S. Medical Sensors

MDUFA VI, which will set FDA review goals for FY2028 to FY2032, will determine whether review timelines for connected sensors tighten or lengthen. Cybersecurity expectations under Section 524B will shift from submission requirements toward post-market surveillance obligations, favouring vendors with mature software-update infrastructure and documented vulnerability disclosure processes.

Tariff policy arising from the Section 232 investigation and the enlarged Section 48D credit will reshape sourcing decisions by 2032. Domestic chip capacity from fabs in Arizona and Texas will reduce import dependency, while CMS's continuing shift toward value-based payment will reward sensors that demonstrate measurable clinical outcome improvements.